CX 5461

Drug Profile

CX 5461

Alternative Names: CX-5461

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cylene Pharmaceuticals
  • Developer BC Cancer Research Centre; Canadian Cancer Trials Group; Peter MacCallum Cancer Centre; Senhwa Biosciences
  • Class Amides; Antineoplastics; Heterocyclic compounds with 4 or more rings; Pyrazines; Small molecules; Thiazoles
  • Mechanism of Action RNA polymerase I inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Haematological malignancies

Most Recent Events

  • 09 Dec 2017 Efficacy, safety and pharmacokinetics data from a phase I trial in Haematological malignancies presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-HEM 2017)
  • 01 May 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in Canada (IV) (NCT02719977)
  • 16 Apr 2016 Preclinical trials in Solid tumours and Haematological malignancies in Canada before April 2016 (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top